Close

SOPHiA GENETICS and Leading US Cancer Center Collaborate to Combine Cancer Analysis Technology for Liquid Biopsies

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

WHO Supplies Medical Equipment for Post-Marburg...

In a recent move, the World Health Organization has...

Life Sciences Sector Plan Sets UK...

Main Article: UK Life Sciences Sector Plan Sets Sights...

UK Government Launches Ambitious Life Sciences...

Government Unveils Life Sciences Roadmap for Growth and Innovation London,...

Highly Customized Treatments to Offer Specialized...

The Human Medicines Regulations 2025, which came into force...

SOPHiA GENETICS™, a cloud-native software company in the healthcare space, has entered an agreement with Memorial Sloan Kettering Cancer Center (MSK) to offer clinicians and researchers new solutions to expand their testing and analytical capabilities. This includes incorporating proprietary Comprehensive Genomic Panel (CGP) sequencing tests such as MSK-ACCESS®, which will be commercialized by SOPHiA GENETICS as the first comprehensive ctDNA liquid biopsy test powered by the SOPHiA DDMTM Platform. By combining predictive algorithms, the power of the global SOPHiA GENETICS network, and the clinical expertise of MSK in cancer genomics, experts hope to expand access to precision cancer analysis capabilities.

Together, SOPHiA GENETICS and MSK will collaborate to further develop MSK-ACCESS®, ensuring the solution takes advantage of the sophisticated analytics of the SOPHiA DDMTM platform. The improved assay will be designed to align with the most recent guidelines and clinical trial data reflecting major actionable biomarkers.

“We’ve already had great collaboration in our discussions with MSK and we see opportunity for building new solutions together that will drive access to important data,” said Jurgi Camblong, Cofounder and CEO of SOPHiA GENETICS. “By raising the bar for more effective collective intelligence, we can create a new gold standard for cancer care.”

As part of this agreement, SOPHiA GENETICS intends to build a new clinico-genomic, cloud-native analytics platform that furthers the impact of MSK’s extensive precision oncology data. This includes the use of advanced machine learning algorithms to analyze extensive multimodal data points to gain new insights. The goal of the new SOPHiA CarePathTM module, paired with MSK’s CGP sequencing tests, is to help inform and improve cancer care globally.

“We’re pleased to be collaborating with SOPHiA GENETICS to bring our advanced precision oncology tools to a more diverse, global population of people with cancer,” said Kojo S. J. Elenitoba-Johnson, MD, Chair of the Department of Pathology and Lab Medicine at MSK. “We believe accelerating access to precision medicine, both in research and in patient care settings, can improve cancer care and yield a wealth of scientific data to advance our mission of reducing the burden of cancer worldwide.”

 

Latest stories

Related stories

WHO Supplies Medical Equipment for Post-Marburg Virus Heal

In a recent move, the World Health Organization has...

Life Sciences Sector Plan Sets UK on Global Growth Track

Main Article: UK Life Sciences Sector Plan Sets Sights...

UK Government Launches Ambitious Life Sciences Sector Plan

Government Unveils Life Sciences Roadmap for Growth and Innovation London,...

Highly Customized Treatments to Offer Specialized Care to UK

The Human Medicines Regulations 2025, which came into force...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back